2026-10-12 ワシントン大学セントルイス校
The study examined the use of an HCV treatment in 14 pregnant patients.
＜関連情報＞
- https://source.washu.edu/2026/10/new-research-shows-promise-for-treating-hepatitis-c-in-pregnancy/
- https://infectiousdiseases.wustl.edu/new-research-shows-promise-for-treating-hepatitis-c-in-pregnancy/
- https://academic.oup.com/cid/article/83/3/e533/8750982
妊娠中のグレカプレビル・ピブレンタスビルによるC型肝炎治療の実臨床経験 Real-World Experience of Hepatitis C Treatment With Glecaprevir-Pibrentasvir During Pregnancy
L Madeline McCrary, Megan R Curtis, Jeannie C Kelly, Jessica Elrod-Gallegos, Patrick Kojima, Patricia Werner, Jennifer L Mullersman, Tracey Habrock-Bach, Michael J Durkin, Laura R Marks
Clinical Infectious Diseases Published:11 August 2026
DOI:https://doi.org/10.1093/cid/ciag422
Abstract
Guidelines endorse antenatal hepatitis C virus treatment following shared decision making. No clinical trial or real-world data exist for glecaprevir-pibrentasvir (GLE/PIB). We report our experience with prenatal GLE/PIB in 14 patients. Ten patients completed treatment; all achieved virologic response by or at delivery, with no maternal or neonatal safety concerns.
